-
公开(公告)号：US20120014950A1
公开(公告)日：2012-01-19
申请号：US13217023
申请日：2011-08-24
申请人： Thi-Sau Migone , Chih-Hung Lo , Luke Oh , Heather Wasserman , Madhav Devalaraja , Matthew J. Bernett
发明人： Thi-Sau Migone , Chih-Hung Lo , Luke Oh , Heather Wasserman , Madhav Devalaraja , Matthew J. Bernett
IPC分类号： A61K39/395 , A61P29/00 , A61P37/02 , A61P19/10 , A61P1/00 , A61P25/00 , A61P37/08 , A61P35/00 , C07K16/00 , A61P19/02
CPC分类号： C07K16/2878 , A61K2039/505 , C07K2317/24 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The present invention relates to antibodies, antibody fragments, and related molecules that specifically bind to DR3 receptors. Such antibodies have uses, for example, in the prevention, detection, diagnosis, treatment or amelioration of a disease or disorder, especially inflammatory and autoimmune diseases and other immune system disorders, such as Crohn's disease, colitis, Inflammatory Bowel Disease, arthritis, asthma, Multiple Sclerosis, atherosclerosis, and allergic disorders. The invention also relates to nucleic acid molecules encoding anti-DR3 receptor antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially inflammatory or autoimmune disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that specifically bind to DR3 receptor.
摘要翻译： 本发明涉及特异性结合DR3受体的抗体，抗体片段和相关分子。 这样的抗体具有例如用于预防，检测，诊断，治疗或改善疾病或病症，特别是炎症和自身免疫疾病和其他免疫系统疾病如克罗恩病，结肠炎，炎症性肠病，关节炎，哮喘 ，多发性硬化症，动脉粥样硬化和过敏性疾病。 本发明还涉及编码抗DR3受体抗体的核酸分子，含有这些核酸的载体和宿主细胞及其制备方法。 本发明涉及用于预防，检测，诊断，治疗或改善疾病或病症，特别是炎性或自身免疫性疾病的方法和组合物，其包括向动物（优选人）施用有效量的一种或多种抗体或片段或 其变体或相关分子，其特异性结合DR3受体。
-
公开(公告)号：US20130089550A1
公开(公告)日：2013-04-11
申请号：US13710305
申请日：2012-12-10
IPC分类号： C07K19/00
CPC分类号： C07K14/70521 , A61K38/00 , C07K16/46 , C07K19/00 , C07K2319/30 , C07K2319/31 , C07K2319/74
摘要： The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
摘要翻译： 本申请涉及靶向CD80和CD86的CTLA4-Ig免疫粘附素及其用途，特别是用于治疗目的。
-
公开(公告)号：US20120082664A1
公开(公告)日：2012-04-05
申请号：US13221811
申请日：2011-08-30
申请人： Matthew J. Bernett , Seung Yup Chu , John R. Desjarlais , Sher Bahadur Karki , Gregory Alan Lazar , Erik WeiKing Pong , John O. Richards , Eugene Alexander Zhukovsky
发明人： Matthew J. Bernett , Seung Yup Chu , John R. Desjarlais , Sher Bahadur Karki , Gregory Alan Lazar , Erik WeiKing Pong , John O. Richards , Eugene Alexander Zhukovsky
IPC分类号： A61K39/395 , A61P35/00 , A61P35/02 , C07K16/28 , C12N15/13
CPC分类号： C07K16/2896 , C07K16/2803 , C07K2317/24 , C07K2317/41 , C07K2317/52 , C07K2317/565 , C07K2317/72 , C07K2317/732 , C07K2317/77 , C07K2317/92 , C07K2317/94
摘要： The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcγR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.
摘要翻译： 本发明描述了靶向CD19的抗体，其中所述抗体相对于亲本抗体包含至少一个修饰，其中与亲本抗体相比，该修饰改变对FcγR的亲和力或改变效应子功能。 还公开了使用本发明的抗体的方法。
-
公开(公告)号：US20110287032A1
公开(公告)日：2011-11-24
申请号：US13032491
申请日：2011-02-22
IPC分类号： A61K39/44 , A61P37/00 , A61P1/00 , A61P19/04 , A61P25/00 , C12P21/00 , A61P29/00 , A61P1/04 , A61P37/06 , C07H21/04 , C12N5/10 , C07K16/18 , A61P17/06
CPC分类号： C07K14/70521 , A61K38/00 , C07K16/46 , C07K19/00 , C07K2319/30 , C07K2319/31 , C07K2319/74
摘要： The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
摘要翻译： 本申请涉及靶向CD80和CD86的CTLA4-Ig免疫粘附素及其用途，特别是用于治疗目的。
-
公开(公告)号：US07749956B2
公开(公告)日：2010-07-06
申请号：US11421060
申请日：2006-05-30
申请人： Jonathan Zalevsky , Duc-Hanh Thi Nguyen , Gregory L. Moore , Sergei A. Ezhevsky , John R. Desjarlais , Arthur J. Chirino , Darian Cash , Matthew J. Bernett
发明人： Jonathan Zalevsky , Duc-Hanh Thi Nguyen , Gregory L. Moore , Sergei A. Ezhevsky , John R. Desjarlais , Arthur J. Chirino , Darian Cash , Matthew J. Bernett
CPC分类号： A61K38/2264 , A61K31/155 , A61K38/28 , A61K2300/00
摘要： A method of treating a mammal with an adiponectin mediated disorder comprising administering a therapeutically effective amount of an adiponectin variant with at least a 3-fold increased solubility relative to residues 110-244 of human adiponectin.
摘要翻译： 一种用脂联素介导的病症治疗哺乳动物的方法，包括给予治疗有效量的脂联素变体，相对于人脂连蛋白的残基110-244，其具有至少3倍增加的溶解度。
-
6.发明申请HUMAN EQUIVALENT MONOCLONAL ANTIBODIES ENGINEERED FROM NONHUMAN VARIABLE REGIONS 有权人类可变区域工程人类等效单克隆抗体公开(公告)号：US20100004431A1
公开(公告)日：2010-01-07
申请号：US12426785
申请日：2009-04-20
CPC分类号： C07K16/00 , C07K16/22 , C07K16/2866 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/567
摘要： The present invention is directed to the creation of human equivalent CDRs and antibodies containing them by a method of producing an antibody which specifically binds to an antigen.
摘要翻译： 本发明涉及通过产生与抗原特异性结合的抗体的方法来产生含有它们的人等效CDR和抗体。
-
公开(公告)号：US20090162382A1
公开(公告)日：2009-06-25
申请号：US12016884
申请日：2008-01-18
IPC分类号： A61K39/395 , C07K16/44 , C07H21/04 , A61P35/00
CPC分类号： C07K16/30 , C07K16/40 , C07K2317/56 , C07K2317/565 , C07K2317/72 , C07K2317/732
摘要： The present invention describes antibodies that target CA9, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcγR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.
摘要翻译： 本发明描述了靶向CA9的抗体，其中所述抗体相对于亲本抗体包含至少一个修饰，其中与亲本抗体相比，该修饰改变对FcγRR的亲和力或改变效应子功能。 还公开了使用本发明的抗体的方法。
-
公开(公告)号：US20080254027A1
公开(公告)日：2008-10-16
申请号：US11982231
申请日：2007-10-31
申请人： Matthew J. Bernett , Seung Yup Chu , John R. Desjarlais , Sher Bahadur Karki , Erik WeiKing Pong , Eugene Alexander Zhukovsky
发明人： Matthew J. Bernett , Seung Yup Chu , John R. Desjarlais , Sher Bahadur Karki , Erik WeiKing Pong , Eugene Alexander Zhukovsky
IPC分类号： A61K39/395 , C07K16/28 , C07H21/04 , A61P35/02 , C12N5/06
CPC分类号： C07K16/2896 , C07K2317/24 , C07K2317/72 , C07K2317/73 , C07K2317/732 , C07K2317/92
摘要： The present invention describes antibodies that target CD5, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcγR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.
摘要翻译： 本发明描述了靶向CD5的抗体，其中所述抗体相对于亲本抗体包含至少一个修饰，其中与亲本抗体相比，该修饰改变对FcγR的亲和力或改变效应子功能。 还公开了使用本发明的抗体的方法。
-
公开(公告)号：US20080219974A1
公开(公告)日：2008-09-11
申请号：US11857310
申请日：2007-09-18
申请人： Matthew J. Bernett , John R. Desjarlais , Sher Bahadur Karki , Gregory Alan Lazar , Umesh S. Muchhal , Duc-Hanh Thi Nguyen , John O. Richards
发明人： Matthew J. Bernett , John R. Desjarlais , Sher Bahadur Karki , Gregory Alan Lazar , Umesh S. Muchhal , Duc-Hanh Thi Nguyen , John O. Richards
IPC分类号： A61K39/395 , C07K16/18 , A61P37/00 , C07H21/00
CPC分类号： C07K16/2896 , A61K2039/505 , C07K2317/24 , C07K2317/72 , C07K2317/732 , C07K2317/92
摘要： The present disclosure describes antibodies that target HM1.24. In various aspects, the antibodies have specific CDR, variable, or full length sequences, have modifications with the parent antibody, or include at least one modification relative to a parent antibody that alters affinity to an FcγR or alters effector function as compared to the parent antibody. Nucleic acids encoding the antibodies and methods of using the antibodies are also disclosed.
摘要翻译： 本公开描述了靶向HM1.24的抗体。 在各个方面，抗体具有特异性CDR，可变或全长序列，与亲本抗体具有修饰，或者相对于亲本抗体，相对于母体抗体，包括改变对FcγRR的亲和力或改变效应子功能的亲本抗体的至少一个修饰 抗体。 还公开了编码抗体的核酸和使用抗体的方法。
-
公开(公告)号：US08637641B2
公开(公告)日：2014-01-28
申请号：US13194904
申请日：2011-07-29
CPC分类号： C07K16/22 , A61K2039/505 , C07H21/00 , C07K16/00 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/94
摘要： The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. increased serum half-life in vivo.
摘要翻译： 本发明一般涉及用于改变抗体的等电点的组合物和方法，并且在一些情况下导致改善的血浆药代动力学，例如， 增加体内血清半衰期。
-
-
-
-
-
-
-
-
-
搜索结果
30 条记录 (耗时 0.071 秒)
